ReviewClinical cardiology2016
Ranolazine in Cardiac Arrhythmia.
Review in Clinical cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Voltage-gated sodium channels in excitable cells as drug targets.Nature reviews. Drug discovery · 2025Review
- The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice.Communications biology · 2023Article
- Predicting human cardiac QT alterations and pro-arrhythmic effects of compounds with a 3D beating heart-on-chip platform.Toxicological sciences : an official journal of the Society of Toxicology · 2023Article
- Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?Sultan Qaboos University medical journal · 2018Review
- Ranolazine: safe and effective in a patient with hypertensive cardiomyopathy and multiple episodes of electrical storm.Clinical case reports · 2017Article
- Sodium channel biophysics, late sodium current and genetic arrhythmic syndromes.Pflugers Archiv : European journal of physiology · 2017Review
- Efficacy of ranolazine in preventing atrial fibrillation following cardiac surgery: Results from a meta-analysis.Journal of arrhythmia · 2017Review
- Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study).Cardiology and therapy · 2017Article
- Advancements in pharmacotherapy for angina.Expert opinion on pharmacotherapy · 2017Review
- Optimization of anFrontiers in physiology · 2017Article
- Ranolazine is an Effective and Safe Treatment of Adults with Symptomatic Premature Ventricular Contractions due to Triggered Ectopy.The International journal of angiology : official publication of the International College of Angiology, Inc · 2016Article
- Experimental and early investigational drugs for angina pectoris.Expert opinion on investigational drugs · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ranolazine utilization in the management of refractory angina has been established by multiple randomized clinical studies. However, there is growing evidence showing an evolving role in the field of cardiac arrhythmias. Multiple experimental and clinical studies have evaluated the role of ranolazine in prevention and management of atrial fibrillation, with ongoing studies on its role in ventricular arrhythmias. In this review, we will discuss the pharmacological, experimental, and clinical evidence behind ranolazine use in the management of various cardiac arrhythmias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.